“Buy When There’s Blood in the Streets”
The phrase “buy when there is blood in the streets” is attributed to Baron Rothschild, a prominent 18th-century banker, who said that the time to invest is when everyone else is panicking and selling their investments.
This quote has become popular in investment circles and is still relevant today.
The idea behind this phrase is simple: when there is a financial crisis or a significant market correction, it creates panic among investors, and they start selling their investments at a discount.
This leads to a sharp decline in prices, creating an opportunity for savvy investors to buy assets at a much lower price than their true value.
The stock that I’m profiling this week is a “blood in the streets” type of stock.
It has prime real estate in New York City, but limited cash flow.
As a result, the stock chart looks like death.
Nonetheless, the underlying assets look very sold.
And insiders have bought all the way down.
I think there is material upside in the stock.
Without further ado, let’s discuss Trinity Place Holdings (TPHS).
New Recommendation- Trinity Place Holdings: High Risk, High Reward
Company: Trinity Place Holdings Inc.
Market Cap: $11 million
Price Target: 1.00
Total Return Potential: 300%
Recommendation: Buy under 0.40
Recommendation Type: Quick Trade
Trinity Place Holdings is a high-risk, high-reward stock. I see a legitimate case for the stock to go up 7x. At the same time, the stock could decline by 100%. The company’s real estate is well-located and based in New York City. The stock represents an asymmetric opportunity with a 7 to 1 upside-to-downside ratio. Insiders own a significant portion of shares.
Trinity Place Holdings Inc. is a publicly traded real estate company headquartered in New York City. The company is focused on the development, ownership, and management of high-quality commercial and residential properties primarily in downtown Manhattan.
Trinity Place Holdings was originally formed as a spin-off from Syms Corp, a former retail chain, in 2012. Since then, the company has embarked on a number of notable real estate projects in New York City, including the development of a luxury residential building at 77 Greenwich Street and the conversion of the historic Trinity Place department store into a mixed-use commercial and residential property.
Trinity Place’s stock chart looks like a disaster.
This is primarily due to the company being asset-rich but cash-poor and investor concern that equity will need to be raised that will dilute shareholders.
However, I believe the company will be able to successfully manage its way through debt maturities and raise enough equity from insiders to manage its current cash crunch.
Today, Trinity Place’s main holdings include:
77 Greenwich, Manhattan, New York
77 Greenwich Street is a luxury residential building located in the heart of Manhattan’s Financial District. The building is situated on a prime corner lot and rises 42 stories high, offering stunning views of the New York City skyline and the Hudson River.
The building features a contemporary, glass and steel facade and offers 90 spacious residences, including one- to four-bedroom apartments, penthouses, and townhouses.
77 Greenwich Street is also home to the K-8 school, Saint Joseph School, which occupies the first eight floors of the building. This unique arrangement provides families with the added convenience of having a top-rated school right in the building.
237 11th Street, Brooklyn, New York
“237 11th” is a 105-unit, 12-story multi-family property located at 237 11th Street in Brooklyn, New York.
The outlook for Trinity Place Holdings is uncertain.
And that’s what creates the opportunity.
The biggest question mark is 77 Greenwich, the building that is located in Manhattan.
The building is almost completed, and 28 residential units have been sold. 62 remain to be sold as of December 31, 2022.
Unfortunately, sales of condos remain slow given an uncertain macro environment.
All proceeds from condo sales will be used to repay debt associated with 77 Greenwich.
Besides 77 Greenwich, Trinity Place has several other valuable assets which I will cover in my valuation.
As Cabot Micro-Cap Insider subscribers know, insider ownership is high on my checklist and is critical when investing in micro-caps.
Insiders, the board of directors, and employees own over 9% of shares outstanding. This ensures that we are well aligned.
Further, MFP Partners, the investment vehicle of the late value investor Michael Price, owns 24.8% of shares.
Insiders have been buying over the past year.
Valuation and Price Target
Trinity Place currently has a market cap of $11MM and an enterprise value of $248MM.
Trinity Place has 4 key assets:
1) A condo building in Manhattan called 77 Greenwich.
2) An apartment building in Brooklyn called 237 11th Street.
3) Potential proceeds from a lawsuit.
4) Net operating losses (NOL).
Let’s attempt to value them.
We can start with the biggest asset, 77 Greenwich.
It is nearing completion of development as a mixed-use project consisting of a 90-unit residential condominium tower, retail space and a New York City elementary school.
TPHS has sold 28 residential condos and 62 remain available to be sold.
Assuming each condo is eventually sold for $3.2M implies $198MM of proceeds from condo sales.
There is also 75,000 square feet of retail space at the bottom of the building.
Assuming a 5% cap rate, this retail space is worth ~$15MM.
237 11th Street
Next, we have a multi-family property: 237 11th Street in Brooklyn. 237 11th Street has 105 units (100% occupancy) and 5k of retail square footage.
TPHS paid $81MM for it & management believes it’s worth “significantly” more today.
I had an independent NYC real estate expert look at the property and he valued it conservatively at $70MM.
Let’s use his number to be conservative (dispute management’s optimism).
Another potential asset is a lawsuit that Trinity Place filed against the seller of 237 11th due to water damage & other building defects.
The lawsuit seeks total damages of $30MM.
Let’s assume TPHS will receive $10MM in the settlement, to be conservative.
Net Operating Losses (NOL)
Another asset is TPHS’ net operating losses.
As of 12/31/2022, TPHS has $276MM of Federal NOLs.
Assuming a 21% federal tax rate, those NOLs are worth $58MM.
We can cut that value in half to be conservative (who knows if TPHS will be able to utilize them).
Putting It All Together
If you add up the asset values discussed above and subtract net debt, you get to a fair share price of $2.31.
This represents upside of almost 700%.
What’s the catch?
TPHS is burning cash and will need to raise equity or debt financing soon.
Yes, TPHS is generating cash from the sale of 77 Greenwich condos, but all that cash goes to pay off the mortgage that is associated with the property.
So, cash is going to have to be raised, but historically, the existing investors have participated in capital raises to avoid dilution.
Further, the company is reviewing strategic alternatives and evaluating all options to increase liquidity.
Nonetheless, this stock is not for the faint of heart.
There is a significant upside, but there is also significant risk.
Size your position appropriately.
As is always the case, micro-caps are illiquid. Be sure to use limits.
My official rating is Buy under 0.40.
Lender Takes Over Property
- Even if the lender takes over Trinity Place’s real estate assets and the buildings are sold to recoup their losses, I believe there would be significant remaining value after all debts are repaid which would result in equity upside.
Equity Holders Get Diluted
- The company needs to raise cash in order to continue operating. Given high insider ownership, I believe management is incentivized to raise capital in a non-dilutive way. Nonetheless, there is the risk that a secondary offering is priced which dilutes current shareholders.
Changes This Week:
Sell Opera Limited (OPRA) to make room for the new recommendation.
Magenta (MGTA) to Hold
Cogstate Ltd (COGZF) had no company news this week but there was some industry news. Eli Lilly (LLY) announced positive results for its Alzheimer’s drug, donanemab. Patients treated with the drug saw their Alzheimer’s progression slow by 27% versus placebo. Eli Lilly plans to proceed with regulatory submissions to get approval as quickly as possible. I expect FDA approval in late 2023 or early 2024. Cogstate worked with Eli Lilly for its phase III trial of donanemab. If the drug is approved, it will mean significantly more revenue for Cogstate as the additional studies are greenlighted. Cogstate reported fiscal Q3 results on April 26. Revenue declined 15% y/y to $11MM. The revenue shortfall is due to slow patient enrollment in Alzheimer’s clinical trials. This isn’t lost revenue but revenue that has just been pushed out a year or so. Management also mentioned that smaller biotechs are a little more cautious spending money given the macro environment. In the near term, Cogstate has two significant catalysts. 1) Eisai’s LEQEMBI (Alzheimer’s) PDUFA date (FDA decision date) is July 6, 2023. 1) Potential approval for Eli Lilly’s donanemab (Alzheimer’s) in late 2023/early 2024. Positive news for either or both drugs would mean significantly more revenue for Cogstate due to the need for additional clinical trials to expand the drugs’ labels and to monitor the effectiveness of the drugs in real patients. Finally, Cogstate announced that it is actively buying back its own stock. It currently has a $13MM authorization (5% of market cap). While Cogstate’s performance has been disappointing, I remain confident in the long-term outlook. Original Write-up. Buy under 1.80
Copper Property Trust (CPPTL) announced on May 5 that its latest distribution would be $0.100391 (to be paid out on May 9). The distribution is from cash flow that was generated from operations (no asset sales proceeds were included). As such, the run rate yield on the trust is 11%. Pretty attractive. The Trust has pulled back, but this is largely due to rising interest rates which have impacted all real estate companies. Copper Property Trust continues to look attractive. I’m very happy to recommend a security that has no debt, is paying an 11% dividend yield, and is liquidating properties over time. Original Write-up. Buy under 14.00
Currency Exchange International (CURN) had no news this week. It reported another excellent quarter on March 15. Revenue grew 32% to $16.5MM, beating consensus expectations by ~$1MM. While we have grown accustomed to 100%+ revenue growth, typical seasonality is returning to the business (Q1 is typically the weakest quarter while Q3 is typically the strongest). Banknote revenue grew 26% while Payments revenue increased 60%. Currency Exchange’s valuation looks attractive at 9x forward earnings and 7x forward free cash flow. Original Write-up. Buy under 16.00
Epsilon Energy (EPSN) had no news this week. It will report Q1 results this week. It reported solid year-end results on March 23. In 2022, revenue increased 64% to $70MM. Adjusted EBITDA increased 120% to $53MM. During the year, the company bought back 4% of shares outstanding and the board of directors authorized another one-year share repurchase authorization to buy back up to 10% of shares outstanding. The company has hedged ~20% of production at a natural gas price of $3.96. The balance sheet remains strong with $45.8M of net cash, representing 38% of its market cap. While lower natural gas prices will hurt results in 2023, it will still be profitable. In 2020, when natural gas prices were at similar levels, Epsilon generated $15.7MM of adjusted EBITDA. Thus, the stock is trading at just 4.2x 2020 (which I view as trough) EBITDA. This valuation appears compelling. Meanwhile, the company is paying a nice dividend and buying back stock. Original Write-up. Buy under 8.00
Esquire Financial Holdings (ESQ) had no news this week. The company reported a good quarter on April 25. Capital remains strong. Common equity tier 1 ratio stands at 14.89% and would be 12.97% including all after-tax unrealized losses. Tangible common equity to tangible assets stands at 11.77% and would be 11.38% including all after-tax unrealized losses. Credit losses remain low with no non-performing loans and a 1.34% allowance for credit losses. Total deposits increased $100MM to $1.3BN from December 31, 2022, to March 31. Uninsured deposits are just 33% of total deposits, and importantly, more than 90% of uninsured deposits represent clients with full relationship banking (loans, payment processing, and other service-oriented relationships). EPS came in at $1.47 or $5.88 on an annualized basis. As such, the stock is trading at just 6x earnings. Esquire looks compelling. Original Write-up. Buy under 45.00
IDT Corporation (IDT) had no news this week. It reported another solid quarter on March 8. Consolidated revenue decreased 7% due to continued tough comps, but NRS continues to grow like crazy (+103%) and net2phone does as well (+30%). The company generated $23.2MM of consolidated EBITDA. Thus, it’s trading at 6.2x consolidated annualized EBITDA. So, the stock now looks cheap on both a consolidated and SOTP basis. Given challenging market conditions for high-growth companies, IDT’s subsidiaries won’t be spun off soon, but we know that, ultimately, they will be monetized either through a sale or a spin-off. The investment case remains on track. Original Write-up. Buy under 45.00
Kistos PLC (KIST: GB) announced a deal to acquire Mime Petroleum, a Norwegian company, on April 19. I love the structure of the deal. Kistos will pay US$1 plus issue up to 6 million warrants exercisable into new Kistos ordinary shares at a price of 385p each, which represents a premium of 31.4% to the last Kistos trading price. Kistos will assume ~$300MM of debt associated with Mime Petroleum, but after factoring cash both at Kistos and on the Mime balance sheet, net cash is expected to be €5MM. Kistos decided to diversify away from the U.K. and Dutch sectors as punitive windfall tax potential made it difficult for the company to commit capital in those geographies. I will need additional data to complete an updated valuation analysis, but I like the deal and continue to be excited by the prospects for Kistos. Original Write-up. Buy under 7.50
Liberated Syndication (LSYN) is working to gain liquidity for shareholders. I spoke to the CEO on February 17 and got an update. He is pursuing any and all liquidity options for investors including: 1) partnering with a SPAC, 2) merging with another public NOL shell, 3) raising money through an IPO, and 4) taking on private equity. I don’t have a sense of timing in terms of when LSYN shareholders can expect liquidity, but I know it is a big focus for the company. From a financial perspective, Libsyn continues to grow strongly. Revenue grew from $42MM in 2021 to $57MM in 2022. On a pro forma basis (full-year contribution from the acquisition of Julep), revenues are over $60MM. Profitability is down as the company is focused on expanding into the podcasting advertising market which has lower profitability than the hosting business. Still, I’m optimistic that Libsyn has a bright future. Original Write-up. Hold
M&F Bancorp (MFBP) reported excellent earnings on May 5. EPS increased 82% to $0.89. ROE reached 32% vs 12% a year ago. This windfall is due to M&F’s deployment of new capital from the Emergency Capital Investment Program. The bank’s CEO stated, “We are pleased with our results for the first quarter of 2023, which exceeded our expectations. We achieved significantly increased earnings available to stockholders of $1.8 million and achieved a 1.55% return on assets, which is outstanding.” The bank remains overcapitalized with stockholder’s equity representing 26.95% of total assets. Non-performing loans represent 0.19% of total assets. M&F is trading at just 6.5x annualized earnings. I expect EPS to grow to $4.74 in 2025 (this might happen by 2024). Assuming M&F continues to trade at its average P/E multiple of 9.3x, the stock should hit 44.00 by 2025, implying significant upside. Original Write-up. Buy under 21.00
Magenta Therapeutics (MGTA) announced on May 3 that it plans to merge with Dianthus Therapeutics. The stock closed down ~20% but has recovered half the drop since then. The announcement is disappointing as I was hoping Magenta would pay out excess cash and then perhaps merge its public listing with another company that hoped to go public. Pre-merger Magenta shareholders are expected to own 21.3% of the new company. The new company is going to raise $70MM in capital from Fidelity, Venrock Healthcare, and several other institutional investors in conjunction with the merger. The new company will have $180MM of cash and several drugs in development focused on treating autoimmune diseases. I’m going to dig into Dianthus to try to determine how promising it is. At a bare-bones level, pre-merger Magenta shareholders will own 21.3% of $180MM of cash that the new company will have once the merger closes. That represents $39MM of value. Magenta’s current market cap is $43MM. Thus, the market is not giving Magenta much credit for Dianthus’s pipeline. I’m going to do more work to determine if it makes sense to hold the stock through the merger. Original Write-up. Hold
Medexus Pharma (MEDXF) had no news. On April 11, the company announced that it expects record fiscal year results. This is encouraging. On March 22, the company announced that it has secured a new licensing agreement to sell a topical treatment called Terbinafine. The product could be approved in Canada this year. Management hasn’t provided sales potential, but it will be a positive contributor. On March 8, Medexus announced that it has secured new credit facilities amounting to $58.5MM. The interest rate for the facilities is only 8.58%, an attractive rate. The new facilities include a $35 million loan, of which $30MM will be used to repay long-term debt, and an additional $5MM that can be used to pay off debentures. Additionally, there is a possibility of accessing an extra $20MM of uncommitted capital. Medexus plans to use this capital to repay convertible debentures in cash, which could potentially halve the dilution. Overall, this is a big positive. All in all, my conviction level remains high. The stock’s valuation looks cheap. Original Write-up. Buy under 3.50
Merrimack Pharma (MACK) had no news this week. It is a biotech company that has no employees. It relies on contractors to minimize costs. Its sole purpose is to receive milestone payments from Ipsen related to the drug Onivyde. Onivyde will likely be approved for first-line metastatic small-cell lung cancer in early 2024 which will trigger a $225MM royalty payment. Merrimack has committed to distributing any royalty proceeds to investors. I expect Merrimack to distribute $15 per share to investors within ~15 months, representing more than 125% of its current share price. Additional upside can be achieved through future milestone payments. Finally, insiders are buying stock in the open market. Original Write-up. Buy under 12.50
NexPoint (NXDT) had no news this week. I expect it to file its 10-Q shortly. The company filed its 10-K on March 31. A couple takeaways: 1) NexPoint’s current NAV (net asset value) is $25.14. As such, the stock is still trading at a massive discount. 2) NexPoint is trying to refinance its debt ($145MM) for its Cityplace Tower in Dallas. The debt was originally due in September, but the lender has agreed to extend the maturity. Management remains confident that it can complete the refinancing, but I’m watching this closely as Cityplace represents ~10% of NXDT’s NAV. 3) The company authorized a share repurchase agreement in October of $20MM over a two-year period. So far, the company has not bought back any stock. I believe this is because the company is retaining liquidity to support the Cityplace refinancing. NexPoint remains a high-conviction idea. Original Write-Up. Buy under 17.00
Opera (OPRA) continues to perform well but I’m moving it to sell because it’s almost reached my price target of $13 and because I need to make room for my new recommendation. Sell
P10 Holdings (PX) had no news this week. The company filed a Form 4 statement on March 16 that seemed to indicate that an insider is selling. But it appears that the company repurchased those shares at an 8% discount to the market (privately negotiated transaction). What appears like a negative is actually a positive. P10 announced an excellent quarter on March 6. Fee-paying assets under management increased 23% y/y. Revenue increased 32% and adjusted EBITDA grew 29%. P10 continues to benefit from secular tailwinds in the private equity industry. Despite strong growth, P10 trades at just 12.9x EBITDA and just 13x cash earnings. This is too cheap a valuation. The investment case is on track. Original Write-up. Buy under 15.00
RediShred (RDCPF) had no news this week. It reported another excellent quarter on April 21. Revenue grew 57% to $57MM CAD while EBITDA grew 67% to $15.3MM. The strength was driven both by acquisitions but also organic growth. Organic growth is being driven by increased demand for shredding by businesses. Higher fuel costs and driver costs hurt margins, but these are starting to moderate. The stock continues to look cheap at 5.8x forward EBITDA. I continue to see 100% upside over the next 12 months and significantly more upside looking out a few years. Original Write-up. Buy under 3.50
Transcontinental Realty Investors (TCI) had no news this week. The company announced on April 19 that its CEO had resigned. I’m not sure what this means. It could be a prelude to a sale but perhaps I’m just being optimistic. The company filed Q4 and 2022 results on March 24. The results look great. As of December 2022, Transcontinental has $471MM of cash and notes receivable on its balance sheet. Its current market cap is $362MM. The company does have some debt for which it has no recourse as it’s tied to additional real estate that Transcontinental owns. Long story short, this stock is very, very cheap. Unfortunately, there is no hard catalyst now and we don’t know what management is going to do with the stock, but we know that the stock is extremely cheap. Insiders are incentivized to buy out minority shareholders at a premium to the current stock price but at a discount to book value. Currently, the stock trades at a price to book value multiple of just 0.4x. Original Write-up. Buy under 45.00
Truxton (TRUX) reported earnings on April 20. The quarter was solid. EPS came in at $1.47. Asset quality remains high with $0 non-performing loans as of March 31, 2023. The Bank’s capital position remains strong with Tier 1 leverage at 10.3%. The one negative in the quarter was that deposits decreased, albeit slightly (by 4%) from December 31, 2022, to March 31, 2023. I’m going to watch this trend closely to see if it continues. Truxton continues to look attractive at ~10x earnings. This isn’t the most exciting stock, but it’s a slow and steady winner. Original Write-up. Buy under 75.00
Unit Corp (UNTC) had no news this week. I’ve done a lot of work on Unit over the past couple of weeks and believe the company will generate $92MM in free cash flow in 2023, even with depressed natural gas prices. As such, the stock looks compelling at a price to free cash flow multiple of 4.6x and an enterprise value to free cash flow multiple of 3.3x. My conversation with the Unit Corp. CFO in April confirmed that all my assumptions are reasonable/conservative. Here are the key takeaways: 1) Q2 dividend ($2.50) hasn’t been approved by the board yet, but they intend to pay it. They also intend to give a little bit of guidance as to what the quarterly dividend will be going forward. I mentioned that I was a little disappointed that the company wasn’t currently buying back stock at 4x FCF and 3x on an EV/FCF basis and the CFO responded with: “We are subject to earnings blackouts when we can’t buy back stock (current period)” and “The implied dividend yield if you annualize the Q2 dividend is very high.” This comment suggests to me that the Q2 dividend might in fact be a good proxy for the run-rate quarterly dividend. 2) While the strategic process to sell the upstream division is over, “everything is for sale at the right price.” 3) Day rate for BOSS rigs is low-to-mid-$30k range. Expect 100% utilization for 2023. SCR Rig utilization might be lower given the natural gas price pullback. All in all, it was a good update, and I bought more stock recently. Original Write-up. Buy under 65.00
William Penn (WMPN) reported strong quarterly results on April 19. Despite the turmoil in the banking market, William Penn grew deposits in the quarter. The bank remains well capitalized with a tangible common equity ratio of 19.7%. The company continues to aggressively repurchase shares. During the quarter, the Board of Directors authorized a fourth repurchase program to repurchase up to 698,312 shares. The company is being quite aggressive. In the first half of April, it repurchased nearly 400,000 shares in the open market. Tangible book value is $12.54 so the stock is currently trading at 75% of book value. This looks like a compelling valuation. Downside is low given the stock is trading below liquidation value. Original Write-up. Buy under 12.50
Amplify Energy (AMPY) stayed on my watch list this month. In 2021, one of the company’s pipelines ruptured off the coast of California creating a massive oil spill. It turned out the accident was not the fault of Amplify but rather a ship that dragged its anchor across the pipeline. Insurance is going to cover the damages, and the pipeline is almost back. Once the pipeline is completely fixed, the company will be gushing free cash flow. To add to the upside case, Amplify just announced an $85MM (net) settlement with the shipping company that caused the damage. Amplify’s valuation continues to look attractive. My only concern is what Amplify will do with all its cash.
FFBW, Inc (FFBW) stays on my watch list. It is a similar set-up to William Penn Bancorp. It is a thrift that probably will get acquired for a nice premium. The CEO will even get a nice bonus if a sale materializes. The only reason that I went with William Penn Bancorp instead of FFBW is because of the aggressive insider buying currently at William Penn. But FFBW looks like another low-risk idea.
Sandridge Energy (SD) is a new name on my watch list. It is yet another dirt-cheap energy name. It just reported earnings and has $288MM of cash on its balance sheet versus a market cap of $509MM. It generated $30MM of free cash flow in the first quarter of the year. My only question is what management will do with all of the company’s cash. I’m shocked that it isn’t buying back stock hand over fist or paying out dividends.
|Cogstate Ltd (COGZF)||1.7||4/13/22||1.09||-36%||Buy under 1.80|
|Copper Property Trust (CPPTL)||12.93||8/11/22||11.14||2%||Buy under 14.00|
|Currency Exchange (CURN)||14.1||5/11/22||18.52||31%||Buy under 16.00|
|Epsilon Energy (EPSN)||5||8/11/21||5.04||1%||Buy under 8.00|
|Esquire Financial Holdings (ESQ)||34.11||10/10/21||39.04||14%||Buy under 45.00|
|IDT Corporation (IDT)||19.37||2/10/21||32.55||68%||Buy under 45.00|
|Kistos PLC (KIST)||4.79||7/13/22||2.8||-42%||Buy under 7.50|
|Liberated Syndication (LSYN)||3.06||6/10/20||3.75||23%||Hold|
|M&F Bancorp (MFBP)||19.26||11/9/22||23.95||24%||Buy under 21.00|
|Medexus Pharma (MEDXF)||1.78||5/13/20||1.04||-42%||Buy under 3.50|
|Merrimack Pharma (MACK)||11.99||1/11/23||13.03||9%||Buy under 12.50|
|NexPoint Diversified Real Estate Trust (NXDT)||14.15||1/12/22||9.68||-27%||Buy under 17.00|
|Opera Ltd. (OPRA)||7.04||2/8/23||12.94||84%||Sell|
|P10 Holdings (PX)**||2.98||4/28/20||9.99||235%||Buy under 15.00|
|RediShred (RDCPF)||3.3||6/8/22||2.99||-9%||Buy under 3.50|
|Transcontinental Realty Investors (TCI)||40.22||10/13/22||35.41||-12%||Buy under 45.00|
|Trinity Place Holdings Inc. (TPHS)||--||NEW||--||--%||Buy under 0.40|
|Truxton Corp (TRUX)*||72.25||12/8/21||58||-16%||Buy under 75.00|
|Unit Corp (UNTC)||57.44||12/14/22||43.26||-6%||Buy under 65.00|
|William Penn Bancorp (WMPN)||11.91||3/8/23||9.65||-11%||Buy under 10.80|
**Original Price Bought adjusted for reverse split.* Return calculation includes dividends
Buy means accumulate shares at or around the current price.
Hold means just that; hold what you have. Don’t buy, or sell, shares.
Sell means the original reasons for buying the stock no longer apply, and I recommend exiting the position.
Sell a Half means it’s time to take partial profits. Sell half (or whatever portion feels right to you) to lock in a gain, and hold on to the rest until another ratings change is issued.
Disclosure: Rich Howe owns shares in PX, MEDXF, LSYN, IDT, DMLP, NXDT, KIST, and RDCPF. Rich will only buy shares after he has shared his recommendation with Cabot Micro-Cap Insider members and will follow his rating guidelines.
The next Cabot Micro-Cap Insider issue will be published on June 7, 2023.